4CMenB has the potential to reduce serogroup B meningococcal disease substantially. Despite its potential, the vaccine may have some limitations, and it remains to be seen if booster doses will be required to sustain protection.
The authors describe the epidemiology of invasive Hib and nontype b H. influenzae infections in children <15 years of age in the United Kingdom from 1994 until 2008, and show that the resurgence in Hib disease during the years 1999-2003 did not affect the epidemiology of invasive nontype b H. influenzae disease in children, which provides further support against serotype replacement.